Ehrlich v. Phase Forward Inc.

955 N.E.2d 912, 80 Mass. App. Ct. 671
CourtMassachusetts Appeals Court
DecidedOctober 21, 2011
DocketNo. 10-P-1510
StatusPublished
Cited by1 cases

This text of 955 N.E.2d 912 (Ehrlich v. Phase Forward Inc.) is published on Counsel Stack Legal Research, covering Massachusetts Appeals Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ehrlich v. Phase Forward Inc., 955 N.E.2d 912, 80 Mass. App. Ct. 671 (Mass. Ct. App. 2011).

Opinion

Katzmann,

J. This case arises in the world of mergers and acquisitions. The plaintiffs, former shareholders in Phase Forward Incorporated (Phase Forward), appeal from a Superior Court [672]*672judge’s dismissal of their claims against Phase Forward’s directors stemming from that company’s sale to Oracle Corporation and Pine Acquisition Corporation (collectively, Oracle). The plaintiffs alleged that the directors breached their fiduciary duties to Phase Forward’s shareholders, under Delaware law, in conducting the sale process and in failing to disclose material information in the proxy statement provided to shareholders. They also alleged that Phase Forward and Oracle aided and abetted Phase Forward’s directors in the breach. In accordance with Lyondell Chem. Co. v. Ryan, 970 A.2d 235 (Del. 2009) (Lyondell), and well-established principles of Delaware law, we affirm.

Background. We summarize the facts from the amended complaint and the accompanying proxy statement, which we accept as true. At the time they initiated this action, the plaintiffs, Selma Ehrlich and Richard Ehrlich, trustees of the Selma Ehrlich Rev. Trust, owned shares of Phase Forward common stock. Phase Forward was then a publicly traded Delaware corporation with its principal place of business in Waltham. It provided software products and services for use in its customers’ global clinical trial and drug safety monitoring activities. Named as defendants were Phase Forward and Oracle, along with the members of Phase Forward’s board of directors. According to the amended complaint, only one of the directors was employed as a member of Phase Forward’s management.

In 2006, Oracle expressed interest in acquiring Phase Forward, and the two companies discussed the possibility over the next three years. In April, 2009, Oracle offered to purchase Phase Forward for $16 per share. Phase Forward’s board of directors established a special committee of independent and disinterested directors to consider the offer, and sought the advice of Thomas Weisel Partners (TWP), an investment banking firm. TWP contacted four potential purchasers to determine market interest in Phase Forward; none came forward. Ultimately, Phase Forward rejected the offer.

In March, 2010, Oracle renewed its offer of $16 per share. Phase Forward again established a special committee of independent and disinterested directors and authorized TWP to contact potential purchasers to test the market. TWP contacted five [673]*673companies, but again, none was interested. Phase Forward rejected Oracle’s offer, and Oracle increased the offer to $16.75, and then to $17 per share, for a total purchase price of approximately $756 million. At that time, the price of $17 per share represented approximately a thirty percent premium over the trading price of Phase Forward stock. Phase Forward’s directors determined that the offer appeared to provide substantial value to the shareholders and could well exceed the potential for growth in the value of the shares should Phase Forward continue as a stand-alone entity. TWP provided an opinion that the price to be paid Phase Forward’s shareholders was fair.

Phase Forward’s board negotiated with Oracle for a reduction in the termination fee4 and a “fiduciary out” provision that allowed the board to consider unsolicited offers from other companies after the proposed merger was announced. On April 15, 2010, the board of directors, the majority of whom were disinterested, unanimously approved the offer and announced the merger the following day. No other companies came forward with offers to purchase Phase Forward after the merger was announced.

On May 14, 2010, Phase Forward filed a preliminary proxy statement with the United States Securities and Exchange Commission (SEC); Phase Forward followed with a definitive proxy statement on May 24, 2010.5 The proxy statement, which was sent to Phase Forward’s shareholders, outlined the process leading to the board’s decision to recommend the merger, summarized the accompanying fairness opinion by TWP and the merger agreement, and disclosed the interests of the directors and executive officers in the merger. Those interests included previously-granted stock options, previously-signed severance [674]*674agreements, and compensation to two directors for their service on the 2010 special committee. The proxy statement also stated that Phase Forward management and employees were expected to continue employment with Oracle after the merger.

After the proxy statement was filed with the SEC, two independent shareholder advisory firms, International Shareholder Services and Glass, Lewis & Co., LLC, advised Phase Forward shareholders to vote for the merger. They based their recommendations, among other things, on the thoroughness of Phase Forward’s sale process.

Shortly after the merger was announced, the plaintiffs filed this action in Superior Court, on behalf of themselves and other Phase Forward shareholders, claiming that the board failed to conduct a thorough and adequate sales process, and that the board provided insufficient information to Phase Forward’s shareholders about the merger. The plaintiffs sought a preliminary injunction to enjoin the shareholder vote on the sale, scheduled for June 22, 2010. The defendants moved to dismiss the complaint for failure to state a claim under Mass.R.Civ.P. 12(b)(6), 365 Mass. 755 (1974). Following lengthy oral argument, a Superior Court judge denied injunctive relief and dismissed the amended complaint. The plaintiffs did not pursue an interlocutory appeal from the denial of their motion for a preliminary injunction. They appeal here from the allowance of the defendants’ motion to dismiss.

Discussion. The parties rely on Massachusetts law regarding the standard for dismissal of a complaint under Mass.R.Civ.P. 12(b)(6), and on Delaware law for the merits, and we do the same. Accordingly, in reviewing the sufficiency of the amended complaint, “[w]e take as true ‘the allegations of the complaint, as well as such inferences as may be drawn therefrom in the plaintiff’s favor.’ ” Golchin v. Liberty Mut. Ins. Co., 460 Mass. 222, 223 (2011), quoting from Blank v. Chelmsford Ob/Gyn, P.C., 420 Mass. 404, 407 (1995). In so doing, we consider the allegations in the complaint, as well as the proxy statement attached thereto. Schaer v. Brandeis Univ., 432 Mass. 474, 477 (2000). “Factual allegations must be enough to raise the right to relief above the speculative level.” Iannacchino v. Ford Motor Co., 451 Mass. 623, 636 (2008), quoting from Bell Atl. Corp. v. Twombley, 550 U.S. 544, 555 (2007).

[675]*6751. Fiduciary duty in conducting the sale. While Delaware courts ordinarily defer to the managerial decisions of directors in accordance with the business judgment rule, the transfer of corporate control has triggered more active judicial oversight. At that point, the directors’ role changes “from defenders of the corporate bastion to auctioneers charged with getting the best price for the stockholders.” Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173, 182 (Del. 1986).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

MAZ Partners LP v. Shear
218 F. Supp. 3d 132 (D. Massachusetts, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
955 N.E.2d 912, 80 Mass. App. Ct. 671, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ehrlich-v-phase-forward-inc-massappct-2011.